logo

China Insulin Drugs And Delivery Devices Market Size (2024 - 2029)

The market size for insulin drugs and delivery devices in China is projected to experience growth over the forecast period, driven by the increasing prevalence of diabetes and the essential role of insulin therapy for managing the condition. Despite the challenges posed by healthcare costs and the need for prescriptions, the market is expected to expand as national health initiatives and systems aim to alleviate patient burdens and ensure access to necessary medications.

Home Market Analysis Healthcare Research Device Drug Combination Research China Insulin Drugs And Delivery Devices Market Market Size

Market Size of China Insulin Drugs And Delivery Devices Industry

China Insulin Drugs And Delivery Devices Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Market Size (2024) USD 6.20 Billion
Market Size (2029) USD 8.90 Billion
CAGR (2024 - 2029) 2.60 %

Major Players

rd-img

*Disclaimer: Major Players sorted in no particular order

China Insulin Drugs And Delivery Devices Market Analysis

The China Insulin Drugs And Delivery Devices Market size is estimated at USD 6.20 billion in 2024, and is expected to reach USD 8.90 billion by 2029, growing at a CAGR of 2.60% during the forecast period (2024-2029).

For a person with type 1 diabetes, insulin therapy is vital for replacing the insulin which the body doesn't produce. People with type 2 diabetes or gestational diabetes need insulin therapy if other treatments, such as diabetes medications and other lifestyle changes, are not able to keep blood glucose levels within the desired range. Diabetes is associated with many health complications. Comparing the population with and without diabetes, those with diabetes have a 300% increased risk of being hospitalized and, thus, incur more healthcare expenses compared to non-diabetic people.

Insulin is a prescription drug in China and requires a prescription. Hospitals are the main places where patients can obtain insulin products. Patients can get medicines directly from the hospital pharmacy without a referral. Despite the implementation of national health insurance and its universal coverage, a large proportion of outpatient drugs is still required to pay. To reduce the burden on patients, China began implementing a National Essential Medicine System, which aims to guarantee the use of drugs by patients.

The rising diabetes prevalence and the aforementioned factors are expected to boost the insulin market's growth.

China Insulin Drugs And Delivery Devices Industry Segmentation

Insulin delivery devices are used to deliver insulin based on a patient's insulin regimen, ability to manipulate or operate a particular device, insurance coverage, or ability to afford a particular device and daily schedule. The China Insulin Drugs and Delivery Devices Market is segmented into Drugs (Basal or Long-acting Insulins, Bolus or Fast-acting Insulins, Traditional Human Insulins, Combination Insulins, and Biosimilar Insulins) and Devices (Insulin Pens, Insulin Pumps, Insulin Syringes, and Jet Injectors). The report offers the value (in USD million) and volume (in million mL) for insulin drugs and (in unit million) for the devices for the above segments.

Drugs
Basal or Long-acting Insulins
Lantus (Insulin Glargine)
Levemir (Insulin Detemir)
Toujeo (Insulin Glargine)
Tresiba (Insulin Degludec)
Basaglar (Insulin Glargine)
Bolus or Fast-acting Insulins
NovoRapid/Novolog (Insulin aspart)
Humalog (Insulin lispro)
Apidra (Insulin glulisine)
FIASP (Insulin aspart)
Admelog (Insulin lispro Sanofi)
Traditional Human Insulins
Novolin/Mixtard/Actrapid/Insulatard
Humulin
Insuman
Combination Insulins
NovoMix (Biphasic Insulin aspart)
Ryzodeg (Insulin degludec and Insulin aspart)
Xultophy (Insulin degludec and Liraglutide)
Soliqua/Suliqua (Insulin glargine and Lixisenatide)
Biosimilar Insulins
Insulin Glargine Biosimilars
Human Insulin Biosimilars
Devices
Insulin Pumps
Insulin Pump Devices
Insulin Pump Reservoirs
Insulin Infusion sets
Insulin Pens
Cartridges in reusable pens
Disposable insulin pens
Insulin Syringes
Insulin Jet Injectors
Need A Different Region Or Segment?
Customize Now

China Insulin Drugs And Delivery Devices Market Size Summary

The China insulin drugs and delivery devices market is poised for significant growth over the forecast period, driven by the increasing prevalence of diabetes and the rising demand for effective insulin therapies. As the largest population of diabetes patients globally, China faces substantial health challenges, with a notable portion of the population undiagnosed. The government's efforts to promote health awareness, early detection, and chronic disease management, alongside the implementation of the National Essential Medicine System, are expected to bolster market expansion. The market is characterized by a moderate level of consolidation, with key players like Gan & Lee Pharmaceuticals, Medtronic, Eli Lilly and Company, Sanofi, and Novo Nordisk leading innovations in insulin delivery technologies.

Technological advancements in insulin delivery devices, particularly insulin pumps, are anticipated to drive market growth. These devices offer continuous insulin administration, mimicking natural pancreatic function, and are preferred over traditional injection methods due to their precision and reduced discomfort. The integration of continuous glucose monitoring systems further enhances patient care and quality of life, both in ambulatory and hospital settings. The Healthy China 2030 Plan and the government's strategic initiatives to control non-communicable diseases underscore the importance of diabetes management, aiming to increase self-management rates among patients. These factors, combined with ongoing research and development efforts by major industry players, are expected to sustain the market's upward trajectory.

Explore More

China Insulin Drugs And Delivery Devices Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

    3. 1.3 Market Restraints

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Bargaining Power of Suppliers

      2. 1.4.2 Bargaining Power of Consumers

      3. 1.4.3 Threat of New Entrants

      4. 1.4.4 Threat of Substitute Products and Services

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION

    1. 2.1 Drugs

      1. 2.1.1 Basal or Long-acting Insulins

        1. 2.1.1.1 Lantus (Insulin Glargine)

        2. 2.1.1.2 Levemir (Insulin Detemir)

        3. 2.1.1.3 Toujeo (Insulin Glargine)

        4. 2.1.1.4 Tresiba (Insulin Degludec)

        5. 2.1.1.5 Basaglar (Insulin Glargine)

      2. 2.1.2 Bolus or Fast-acting Insulins

        1. 2.1.2.1 NovoRapid/Novolog (Insulin aspart)

        2. 2.1.2.2 Humalog (Insulin lispro)

        3. 2.1.2.3 Apidra (Insulin glulisine)

        4. 2.1.2.4 FIASP (Insulin aspart)

        5. 2.1.2.5 Admelog (Insulin lispro Sanofi)

      3. 2.1.3 Traditional Human Insulins

        1. 2.1.3.1 Novolin/Mixtard/Actrapid/Insulatard

        2. 2.1.3.2 Humulin

        3. 2.1.3.3 Insuman

      4. 2.1.4 Combination Insulins

        1. 2.1.4.1 NovoMix (Biphasic Insulin aspart)

        2. 2.1.4.2 Ryzodeg (Insulin degludec and Insulin aspart)

        3. 2.1.4.3 Xultophy (Insulin degludec and Liraglutide)

        4. 2.1.4.4 Soliqua/Suliqua (Insulin glargine and Lixisenatide)

      5. 2.1.5 Biosimilar Insulins

        1. 2.1.5.1 Insulin Glargine Biosimilars

        2. 2.1.5.2 Human Insulin Biosimilars

    2. 2.2 Devices

      1. 2.2.1 Insulin Pumps

        1. 2.2.1.1 Insulin Pump Devices

        2. 2.2.1.2 Insulin Pump Reservoirs

        3. 2.2.1.3 Insulin Infusion sets

      2. 2.2.2 Insulin Pens

        1. 2.2.2.1 Cartridges in reusable pens

        2. 2.2.2.2 Disposable insulin pens

      3. 2.2.3 Insulin Syringes

      4. 2.2.4 Insulin Jet Injectors

China Insulin Drugs And Delivery Devices Market Size FAQs

The China Insulin Drugs And Delivery Devices Market size is expected to reach USD 6.20 billion in 2024 and grow at a CAGR of 2.60% to reach USD 8.90 billion by 2029.

In 2024, the China Insulin Drugs And Delivery Devices Market size is expected to reach USD 6.20 billion.

China Insulin Drugs And Delivery Devices Market Report Snapshots

China Insulin Drugs and Delivery Devices Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)